BLT
05/10/2015 13:51
GENERAL
NOT PRICE SENSITIVE
REL: 1351 HRS BLIS Technologies Limited
GENERAL: BLT: Ear Infections Reduced Through Use Of Blis K12
News Release
For immediate release
October 5, 2015
Ear Infections Reduced Through Use Of Blis K12 - Italian Clinical Study
The International Journal of General Medicine reports findings of an Italian
clinical study showing the daily use of BLIS K12 reduced the rate of ear
infections (acute otitis media) by over 40% when compared to diagnosed
infections from the same populations in the prior 12 months.
In addition, there was a 50-60% improvement in specific measurements for
hearing (p<0.01) as well as an approximate 40% improvement in the appearance
of the ear canal and eardrum (p<0.05), including reductions in fluid build-up
in the middle ear.
Those latest results confirm and extend earlier findings in both children and
adults, establishing the importance of a healthy oral cavity microbiome and
demonstrating the striking benefits of daily BLIS K12 supplementation in
promoting oral health.
The results of this study also reconfirm the excellent safety profile of BLIS
K12 in children with no adverse effects reported.
In this pilot study, conducted by a Milan-based research team, 22 children
ages 3-9 years old with a recent history of acute otitis media and fluid in
one or both ears for at least two months were selected for participation in
the study. They were each administered a once daily chewable lozenge
containing BLIS K12.
Middle ear infections are common in children affecting 80% of children at
some time during their childhood. Acute otitis media can become a lingering
problem resulting in an inflammatory condition characterised by persistent
fluid in the middle ear cavity. If left untreated it can lead to
hearing-related complications.
NZX-listed Blis Technologies chief executive Barry Richardson said the latest
trial followed three previous successful trials by the same Italian group.
One of those previous trials using BLIS K12 on strep throat indicated a
secondary effect of reduction of ear infections so this trial follows up that
observation.
Blis Technologies commercialised the BLIS K12 strain of Streptococcus
salivarius that has resulted from research carried out at the University of
Otago by Professor John Tagg.
END
For further comment contact:
Barry Richardson 021 664 742
For media assistance contact:
Del Carlini 021 709 907
End CA:00271289 For:BLT Type:GENERAL Time:2015-10-05 13:51:18
